2024-02-05 11:04:56 ET
Summary
- DocGo has recently faced a series of negative events, including criticism from the NY Times, Comptroller contract rejection, CEO departure on false CV allegations, and a short report.
- Despite these challenges, the company presented strong Q3 2023 results, positively revised FY 2023 guidance, addressed the short report, announced new partnerships and a share repurchase program.
- Investors must decide if they should trust DocGo's performance and financials or let the dust settle first.
Thesis
DocGo Inc. ( DCGO ) is a mobile health and medical transportation company growing profitably, aspiring to revolutionize healthcare. I published an intro on DocGo and shared my point of view in a previous article . The company has kept growing profitably since then, meeting or beating expectations; however, a series of unexpected events have occurred since last July....
Read the full article on Seeking Alpha
For further details see:
DocGo: Good Performance, Trust Issues